Cynata Therapeutics (CYP) reported positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus mesenchymal stem cell product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). These findings, together with the excellent data from Cohort A, support the advancement of CYP-001 into a Phase 2 trial in GvHD
http://crweworld.com/article/news-p...-cohort-b-of-phase-1-trial-of-cyp-001-in-gvhd
- Forums
- ASX - By Stock
- CYP
- Ann: Positive 28-day Clinical Trial Data in Cohort B
Ann: Positive 28-day Clinical Trial Data in Cohort B, page-45
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.21M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 54623 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 21953 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 54623 | 0.225 |
1 | 35000 | 0.220 |
1 | 6277 | 0.215 |
1 | 86380 | 0.210 |
3 | 64257 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 21953 | 2 |
0.240 | 95350 | 2 |
0.245 | 21895 | 1 |
0.250 | 42019 | 2 |
0.280 | 5000 | 1 |
Last trade - 11.00am 07/05/2024 (20 minute delay) ? |
|
|||||
Last
22.5¢ |
  |
Change
0.000 ( 6.25 %) |
|||
Open | High | Low | Volume | ||
22.5¢ | 22.5¢ | 22.5¢ | 3000 | ||
Last updated 11.28am 07/05/2024 ? |
Featured News
CYP (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online